Navigation Links
Penn scientists map molecular regulation of fat-cell genetics
Date:11/4/2008

PHILADELPHIA - A research team led by Mitchell Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania School of Medicine, has used state-of-the-art genetic technology to map thousands of positions where a molecular "master regulator" of fat-cell biology is nestled in DNA to control genes in these cells. The findings appear online this week in Genes & Development.

The international obesity epidemic is leading to major health risks, including increased rates of diabetes, heart disease, and cancer. Obesity is caused by increased numbers of fat cells that store more fat than normal. "This research has the potential to lead to new ways to think about therapies aimed at reducing the number of fat cells or altering fat cell function in ways that reduce the complications of obesity," says Lazar.

The master molecule is called PPAR gamma, a gene regulator that is also the target of a major class of antidiabetic drugs, which include Actos and Avandia. PPAR gamma binds directly to DNA, regulating the production of proteins by turning genes on or off. Actos and Avandia are effective in treating diabetes, but their side effects, which include weight gain, prevent them from being recommended as a first-line therapy. The drugs bind to PPAR gamma in the nucleus of fat cells, which affects the expression of many genes, about twenty of which were previously known.

New biocomputing methods allowed first author Martina I. Lefterova, a PhD candidate in the Lazar lab, to discover roughly 5,300 additional sites that PPAR gamma targets in fat-cell DNA. The amount of data is enormous, and may allow additional insights into how fat-cell genes are regulated.

"Until now, we were looking at how PPAR gamma works one gene at a time," says Lazar. "It's like we were peering at the pieces of a jigsaw puzzle in isolation. Now we can look at the full picture." Analysis of the data has already led the Penn team to understand how different factors, including one called C/EBP, cooperate with PPAR gamma to fulfill fat cell functions.

Lefterova used a new technology called Chip on Chip that, in its first step, employs an antibody to isolate the segments of DNA attached to PPAR gamma. Then in the second step, a microarray chip is used to determine the genetic sequences of the isolated DNA.

Decreasing the side effects associated with antidiabetic drugs is the main clinical goal of this work. The major side effects related to the mechanisms of these drugs is increased fat and increased edema, or water weight gain, so understanding exactly where and how these drugs affect gene regulators like PPAR gammawhether their binding to PPAR gamma turns genes on or off--is important.

"We want to be able to determine which genes we want to affect in one case, but not the other, in order to eliminate unwanted side effects, but keep the positive anti-diabetic effects," says Lazar.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Scientists Make Clones of Mice Dead 16 Years
2. Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution
3. Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution
4. Scientists Develop New Strategy to Fight Obesity
5. Scientists Spot 4 New Alzheimers Genes
6. Scientists Identify Brains Hate Circuit
7. Scientists identify new gene responsible for puberty disorders
8. Gladstone scientists identify role of fatty acids in Alzheimers disease
9. Scientists Hot on Trail of New Antibiotics
10. Scientists close in on method to fight deadly childhood cancer
11. NIH scientists discover crucial control in long-lasting immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... , ... August 18, 2017 , ... ... Administration Reauthorization Act of 2017, legislation that provides for greater public access to ... moderate hearing loss to access OTC hearing aids without being seen by a ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the ... there are two sides. There are not two sides to hatred, bigotry, discrimination, and ... and prejudice, and the NPEIV stands against all forms of such hatred and discrimination ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, ... the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the ... Governor for Tourism Products and Business at TAT said, “Thailand has long been ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... O'Fallon, MO (PRWEB) , ... August 18, 2017 , ... ... Charles County, is inaugurating a new charity drive to generate community support for efforts ... for research into cures and treatments for all types of cancer. , Each ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
Breaking Medicine Technology: